^
    2d
    Lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia initially presenting as postmenopausal pelvic pain and bleeding: a rare case report with literature review. (PubMed, Gynecol Oncol Rep)
    To our knowledge, there have been only two cases previously described in the literature of LPL/WM involvement in the female genital tract; both of which had prominent involvement of the ovaries. Although exceedingly rare, LPL/WM involvement of the female genital tract should be considered on the differential diagnosis if atypical lymphoid cells or dense lymphoid aggregates are observed.
    Journal
    |
    MYD88 (MYD88 Innate Immune Signal Transduction Adaptor)
    2d
    Immune receptor translocation-associated protein 1 and myeloid nuclear differentiation antigen are useful markers for the differential diagnosis of marginal zone lymphoma. (PubMed, Pathology)
    Expression of IRTA1 alone, or either IRTA1+ or MNDA+, was less frequent among MZL with plasma cell differentiation than among MZL with classical cell morphology (p=0.063 and 0.071, respectively), albeit not significantly. IRTA1 and MNDA are sensitive and specific markers for the differential diagnosis of MZL, and they may be helpful in distinguishing MZL from histologic mimics.
    Journal
    |
    CCND1 (Cyclin D1) • BCL6 (B-cell CLL/lymphoma 6) • CD5 (CD5 Molecule) • MME (Membrane Metalloendopeptidase) • SOX11 (SRY-Box Transcription Factor 11) • FCER2 (Fc Fragment Of IgE Receptor II)
    2d
    HX009-II-02: Recombinant Humanized Anti-CD47/PD-1 Bifunctional Antibody HX009 in Patients With Relapsed/Refractory Lymphoma (clinicaltrials.gov)
    P1/2, N=48, Completed, Hangzhou Hanx Biopharmaceuticals, Ltd. | Recruiting --> Completed | N=99 --> 48 | Trial completion date: Dec 2026 --> Dec 2025 | Trial primary completion date: Dec 2025 --> Jun 2025
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    HX-009
    5d
    BHARAT-1: A First in Human Study of AUR 103 Calcium to Evaluate Safety, Pharmacokinetics and Pharmacodynamics (clinicaltrials.gov)
    P1, N=27, Terminated, Aurigene Discovery Technologies Limited | N=80 --> 27 | Recruiting --> Terminated; Patient recruitment problems.
    Enrollment change • Trial termination • First-in-human
    |
    AUR-103
    6d
    BGB-16673-102: Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader (clinicaltrials.gov)
    P1/2, N=146, Recruiting, BeiGene | Trial completion date: Sep 2027 --> Jan 2029 | Trial primary completion date: Feb 2026 --> Jan 2029
    Trial completion date • Trial primary completion date
    |
    catadegbrutinib (BGB-16673)
    7d
    Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma (clinicaltrials.gov)
    P1/2, N=20, Recruiting, New York Medical College | Trial completion date: Aug 2025 --> Aug 2027 | Trial primary completion date: Aug 2024 --> Aug 2026
    Trial completion date • Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD34 (CD34 molecule)
    |
    Polivy (polatuzumab vedotin-piiq)
    8d
    CELESTIAL-301: SynKIR-310 for Relapsed/Refractory B-NHL (clinicaltrials.gov)
    P1, N=36, Recruiting, Verismo Therapeutics | N=18 --> 36
    Enrollment change • First-in-human
    |
    BCL2 (B-cell CLL/lymphoma 2)
    9d
    Tanshinone IIA alleviates inflammation and apoptosis in myocardial ischemia-reperfusion injury by modulating the MALT1/NF-κB/NLRP3 signaling axis. (PubMed, Histol Histopathol)
    Tan IIA attenuated I/R-induced myocardial inflammation and apoptosis through the inhibition of the MALT1/NF-κB/NLRP3 signaling pathway, ultimately alleviating myocardial I/R injury.
    Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • MALT1 (MALT1 Paracaspase) • IL18 (Interleukin 18) • NLRP3 (NLR Family Pyrin Domain Containing 3)
    9d
    Endoscopic characteristics of primary gastric lymphoma and prediction of treatment response (PubMed, Beijing Da Xue Xue Bao Yi Xue Ban)
    PGL demonstrates considerable variability in its endoscopic presentation. Features, such as ulcerative/mixed morphology, friability, bleeding tendency, stenosis, and impaired peristalsis are indicative of more aggressive disease and correlate with poorer survival outcomes. The CD21/BCL6-based grading of lymphoid follicular disruption provides a valuable tool for identifying patients at high risk of HPE failure, supporting early intervention and risk stratification for gastric MALT lymphoma treatment.
    Retrospective data • Journal
    |
    BCL6 (B-cell CLL/lymphoma 6)
    14d
    VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma (clinicaltrials.gov)
    P2, N=26, Completed, Henan Cancer Hospital | Recruiting --> Completed | N=60 --> 26 | Trial completion date: Apr 2025 --> Mar 2026 | Trial primary completion date: Dec 2023 --> Jul 2025
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    Rituxan (rituximab) • bortezomib • cyclophosphamide • epirubicin • prednisone
    14d
    Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T (clinicaltrials.gov)
    P1, N=16, Completed, Calibr, a division of Scripps Research | N=36 --> 16 | Trial completion date: Aug 2036 --> Oct 2025 | Trial primary completion date: Aug 2036 --> Oct 2025 | Enrolling by invitation --> Completed
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    CLBR001/SWI019